[Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich]

Herz. 2016 Jun;41(4):271-2. doi: 10.1007/s00059-016-4442-4.

[Article in German]

Authors

R Erbel¹, A K Gitt²

Affiliations

¹ Institut für medizinische Informatik, Biometrie und Epidemilogie (IMIBE), Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland. Raimund.Erbel@uk-essen.de.
² Institut für Herzinfarktforschung Ludwigshafen und Medizinische Klinik B, Klinikum Ludwigshafen, Bremserstr. 79, 67063, Ludwigshafen, Deutschland.

PMID: 27241696
DOI: 10.1007/s00059-016-4442-4

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Anticholesteremic Agents / therapeutic use*
Evidence-Based Medicine
Humans
Hypercholesterolemia / drug therapy*
Hypercholesterolemia / immunology*
Molecular Targeted Therapy / methods
PCSK9 Inhibitors*
Proprotein Convertase 9 / immunology*
Treatment Outcome

Substances

Antibodies, Monoclonal
Anticholesteremic Agents
PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9